Compare BioNano Genomics Inc (BNGO) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs NICE Ltd — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while NICE Ltd trades at $101.27 (market cap $6.00B). The key difference: NICE Ltd is far larger — about 454.5× BioNano Genomics Inc's market cap, and NICE Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | NICE | |
|---|---|---|
Market Cap | $13.20M | $6.00B |
Sector | Health | Technology |
52-Week High | $4.92 | $170.37 |
52-Week Low | $1.09 | $83.15 |
Enterprise Value | $15.81M | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
NICE stock trades at $103.48, up 3.75% today, with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with a 65.79% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.64 beating expectations of $2.52. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, expanding NICE's global footprint in customer experience solutions.
NICE presents a compelling investment case with attractive valuation (P/E 12.13) and 56.5% analyst buy ratings targeting $124.88 consensus. Key risks include execution challenges in AI integration and competitive pressure from larger tech players. The stock's current proximity to 52-week highs requires monitoring for sustainability of recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
